Form Health Reviews Liraglutide
Genuinely used rather than merely listed. Form's formulary breadth and specialist prescribers make it one of the few vendors that will place a member on a cheaper agent when it is clinically appropriate.
Sold as Saxenda, Victoza · Reviewed September 19, 2026
What “First-line” means here
Prescribed as a first-line option. No lower-cost trial is required before a member can start.
The pairing
How Form Health handles Liraglutide
These are the vendor-specific mechanics that determine what this molecule actually costs you and whether members stay on it long enough to benefit.
- Access status
- First-line
- Gating
- Clinician judgment within the step-therapy protocol.
- Prescribes directly
- Yes
- Step therapy
- Yes
- Prior authorization
- Yes
- Titration protocol
- Physician-led with obesity-medicine board certification required for all prescribers
- Off-ramp
- Physician-directed dose reduction with structured maintenance follow-up
- Care team
- Board-certified obesity medicine physicians, Registered dietitians, Nurse practitioners
Ask Form Health this
What share of your starts are liraglutide, and how many of those members never escalate to a weekly agent?
Watch out
Ask about prescriber capacity in your geography. Board-certified obesity medicine is a genuinely scarce specialty.
The molecule
Liraglutide in one page
The first-generation daily GLP-1. Lower efficacy than the weekly agents, but generic entry has made it the cheapest genuine GLP-1 option and a credible step-therapy rung.
Clinical profile
- Drug class
- GLP-1 receptor agonist
- Brand names
- Saxenda — Chronic weight managementVictoza — Type 2 diabetes
- Mechanism
- Single GLP-1 receptor agonist with a shorter half-life than the weekly agents, requiring daily administration to maintain effect.
- Administration
- Once-daily subcutaneous injection. Daily dosing is the main adherence disadvantage versus weekly agents.
- Titration
- Weekly dose escalation over roughly a month to the maintenance dose — a substantially shorter ladder than the weekly agents.
- Typical result
- Average body-weight reduction in the high single digits as a percentage — roughly half what the newer agents produce, though achieved faster and at a fraction of the cost.
- Generic available
- Yes
Known side effects
- Gastrointestinal effects similar in kind to the weekly agents
- Injection-site reactions somewhat more common given daily administration
- Class boxed warning regarding thyroid C-cell tumors observed in rodents
What benefits teams need to know
This is your step-therapy rung
Generic availability makes liraglutide the only GLP-1 that can sit meaningfully below the weekly agents on cost. A vendor that will genuinely trial it before escalating has a real cost-control mechanism; one that lists it and never uses it does not.
Adherence is the honest tradeoff
Daily injection produces worse persistence than weekly dosing. A step-therapy protocol built on this molecule needs to distinguish members who failed on efficacy from members who failed on adherence, because they warrant different escalation decisions.
Alternatives
Other vendors and Liraglutide
Same molecule, materially different access rules. The status column is where the cost difference lives.
| Vendor | Access | Score | PMPM |
|---|---|---|---|
| Omada Health Coaching companion | Companion support | 8.4 | $32–$58 |
| Teladoc Health Navigation & orchestration | Adjunct | 7.4 | $18–$44 |
| 9amHealth Metabolic specialist | Adjunct | 7.3 | $34–$72 |
| Calibrate Full-service clinical | Adjunct | 7.2 | $65–$110 |
| Transcarent Navigation & orchestration | Orchestrated | 7.1 | $12–$32 |
| WeightWatchers Clinic Consumer-brand clinical | Adjunct | 6.9 | $30–$68 |
Same vendor
Form Health across the formulary
How this vendor positions each molecule tells you more about its cost discipline than any single review does.
First-line, prescribed exclusively by physicians board-certified in obesity medicine — the highest clinical bar of any vendor evaluated. Protocol discipline shows up in real-world results tracking unusually close to trial benchmarks.
First-line alongside semaglutide, selected on clinical grounds by an obesity-medicine specialist rather than by formulary default. Physician-directed dose reduction is built into the maintenance plan.
Used alongside incretin therapy for glycemic indications, and as an early rung for members whose presentation warrants it.